merged_engineered-virus-steals-proteins-from-hiv.txt
<question_number>1</question_number>
<answer>TIPs may require only one injection, while lenacapavir requires twice-yearly shots, making TIPs more feasible in resource-limited settings.</answer>

<question_number>2</question_number>
<answer>Reduced H.I.V. transmission rates.</answer>

<question_number>3</question_number>
<answer>TIPs permanently modify the patient's DNA, raising consent issues for potential spread to others.</answer>

<question_number>4</question_number>
<answer>TIPs compete with H.I.V. for resources within cells, interfering with the virus's life cycle.</answer>

<question_number>5</question_number>
<answer>Unexpected side effects may be irreversible due to DNA alteration.</answer>

<question_number>6</question_number>
<answer>TIPs enter protein shells more effectively, leading to the release of more TIPs than H.I.V. particles.</answer>

<question_number>7</question_number>
<answer>Unexpected side effects might be unremovable due to permanent DNA integration.</answer>

<question_number>8</question_number>
<answer>It targets a fundamental aspect of viral replication, making it applicable to other viruses.</answer>

<question_number>9</question_number>
<answer>Consent cannot be obtained from individuals who might be indirectly infected with TIPs.</answer>

<question_number>10</question_number>
<answer>TIPs compete for resources and packaging within cells, while protease inhibitors block specific viral proteins.</answer>